XTX Topco Ltd Invests $249,000 in INmune Bio, Inc. (NASDAQ:INMB)

XTX Topco Ltd purchased a new stake in INmune Bio, Inc. (NASDAQ:INMB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 46,253 shares of the company’s stock, valued at approximately $249,000. XTX Topco Ltd owned about 0.21% of INmune Bio as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Financial Advocates Investment Management increased its stake in shares of INmune Bio by 17.4% during the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 2,000 shares during the period. Jane Street Group LLC bought a new position in INmune Bio during the 3rd quarter worth $79,000. Rhumbline Advisers acquired a new stake in shares of INmune Bio during the second quarter worth $121,000. Fermata Advisors LLC lifted its holdings in shares of INmune Bio by 25.2% during the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after buying an additional 8,590 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares during the period. 12.72% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO David J. Moss purchased 10,000 shares of the stock in a transaction dated Monday, September 30th. The stock was bought at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the acquisition, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at approximately $6,802,247.01. This represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 35.20% of the stock is owned by corporate insiders.

INmune Bio Stock Down 8.2 %

INMB stock opened at $4.57 on Thursday. The company’s 50-day moving average price is $5.31 and its two-hundred day moving average price is $6.58. The firm has a market cap of $101.33 million, a P/E ratio of -2.10 and a beta of 1.79. INmune Bio, Inc. has a 12 month low of $4.45 and a 12 month high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same quarter in the prior year, the firm earned ($0.48) earnings per share. Equities analysts predict that INmune Bio, Inc. will post -2.24 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on INMB shares. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective for the company. Scotiabank began coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price target for the company. Finally, Raymond James assumed coverage on INmune Bio in a research note on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.